From The Editor | October 24, 2013

How Should Big Pharma Partner With Academia? A Perspective From Lilly

By Ed Miseta, Chief Editor, Clinical Leader

Ed Miseta

In preparation for upcoming patent expires, Eli Lilly and Company (NYSE: LLY) has been transforming itself to better deal with the increasing costs of developing life-saving medicines and possible decreases in revenue. One of the primary goals of the company has been to move away from a model where virtually 100% of R&D was in-house. By decreasing fixed expenditures, and increasing flexible spending, the company would be in a better position to manage its clinical and manufacturing costs.

More recently, that plan is evolving into academic partnerships as well. “We are now asking if, in the ecosystem of drug development and discovery, there is a fundamental place where we can work in a systematic way with academic institutions,” says Andy Dahlem, VP of Lilly Research Lab (LRL) Operations and LRL Europe for Eli Lilly and Company. “The proposition has become more interesting because of the increasing pressures being placed on academic institutions and their business model. This is occurring at the same time Pharma faces increased cost pressures.”

access the From The Editor!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma